AAN 2024

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

02:00 PM

Duration 1hr Denver, USA

Teleneurology visits had similar to lower odds of completion of AAN multiple sclerosis quality measures compared to in-person visits

Samantha Stallkamp, Sarita Walvekar, Kelly Brown, Saswat Sahoo, Mengke Du, Elizabeth S. Mearns, Nikki Win, Marisa McGinley

Neuroscience | Multiple Sclerosis

05:45 PM

Duration 1hr Denver, USA

Variation in the Use of Disease-Modifying Therapies in Persons with Multiple Sclerosis by Age

Caroline K Geiger, Rongrong Wang, Carmen Ng

Neuroscience | Multiple Sclerosis

Duration 1hr Denver, USA

Protocol for a Delphi Consensus Panel on Assessing Clinically Meaningful Treatment Outcomes in Adults Living with Spinal Muscular Atrophy (SMA)

K Sully, CA Chiriboga, T Duong, Y Erbas, J Glascock, N Gusset, R Muni-Lofra, C O’Connell, JF Vázquez-Costa, MC Walter, CJ Guittari, J Cochrane, LD Townson, A Marciniak, D Riley, J Nam

Neuroscience | Spinal Muscular Atrophy

Duration 1hr Denver, USA

A retrospective, non-interventional cohort study to compare adults with SMA receiving risdiplam▼ with untreated patients: Study design

CJ Guittari, M Batech, A Carmona, SY Lee, A Poll, A Simpson, S Edwards, CS Sutherland, C Marini-Bettolo, MC Walter, M Jagut, J Haberlová, V Hodgkinson, E Yiu, LB Murphy, TREAT-NMD Global Data systems Oversight Committee (TGDOC), TREAT-NMD Global Registry Network for SMA, T Roe, H Gordish-Dressman

Neuroscience | Spinal Muscular Atrophy

10:08 PM

Duration 12mins S7: Multiple Sclerosis in: Special Populations and Non-MS CNS Neuroinflammatory Diseases

Pregnancy and Infant Outcomes in Females Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of over 3,000 Pregnancies to Date

R Bove, C Pietrasanta, C Oreja-Guevara, K Hellwig, R Dobson, S Vukusic, C-J Lin, D Goncalves Pereira Alves, D Zecevic, G Ferreira, L Craveiro, N Pasquarelli, T McElrath

Neuroscience | Multiple Sclerosis

05:21 PM

Duration 6mins ES1: Emerging Science 1

Oral Presentation: Primary and secondary results of LUMINESCE, a Phase 3 study of interleukin-6 signaling inhibition by satralizumab▼ in generalized myasthenia gravis

Ali. A. Habib, Chongbo Zhao, Inmaculada Aban, Marcondes Cavalcante França Jr., Jorge Gustavo José, Gerd Meyer zu Hörste, Elżbieta Klimiec-Moskal, Michael T. Pulley, Darío Tavolini, Kathleen Blondeau, Petranka Krumova, Siân Lennon-Chrimes, Gian-Andrea Thanei, Ivana Vodopivec, Gil I. Wolfe, Hiroyuki Murai

Neuroscience | Myasthenia gravis

06:10 PM

Duration 30mins Denver, USA

Poster: Primary and secondary results of LUMINESCE, a Phase 3 study of interleukin-6 signaling inhibition by satralizumab▼ in generalized myasthenia gravis

Neuroscience | Myasthenia gravis

11:30 PM

Duration 29mins Denver, USA

Clinical Applications of Digital Biomarkers in Multiple Sclerosis: A Systematic Literature Review

Bryan Cobb, Richard J. Karpowicz, Jr., Chris Cousin, Nikki Win, Tina Boggiano, David E. Jones, Licinio Craveiro, Jessica Priest, Ami Mac, Edmond Teng, E. Ray Dorsey, Marwan N. Sabbagh, Mark Gudesblatt, Bart M. Demaerschalk, David W. Dodick

Neuroscience | Multiple Sclerosis

Duration 29mins Denver, USA

Prediction of Long-Term Adherence to Smartphone Sensor-Based Tests (Floodlight)

MP McGinley, G Pointeau, M Zanon, L Leocani, G Comi, F Lipsmeier, L Craveiro, H Butzkueven

Neuroscience | Multiple Sclerosis

03:15 PM

Duration 15mins Clinical Trials Plenary Session

One-Year Analysis of Efficacy and Safety Data From Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial

Lilyana Amezcua, Nancy L Monson, Mitzi J Williams, Timothy Vartanian, Anthony T Reder, Krupa Pandey, Kottil Rammohan, Barry Hendin, Gregory F Wu, Rikisha Parekh, Jinglan Pei, Ibraheem Abioye, Juan Acosta, Evanthia Bernitsas

Neuroscience | Multiple Sclerosis

Duration 15mins Clinical Trials Plenary Session

Referral Patterns from Primary Care Clinicians to Specialists Among People with Neurological Disorders

Elizabeth S. Mearns, Daniel Sheinson, Kimberly Jinnett, Anisha M. Patel, Abhishek Gaur, Christine J. Macaluso, Jonathan M. Weiss, Nikki Win

Neuroscience | Multiple Sclerosis

Duration 15mins Clinical Trials Plenary Session

Disease Burden of Neurological Disorders in Underserved Populations Across the US in 2022

Anisha M Patel, Elizabeth S Mearns, Stacey Kowal, Katherine L Rosettie, Nikki Win

Neuroscience | Multiple Sclerosis

05:45 PM

Duration 1hr Denver, USA

Estimates of Productivity Loss Due to Neurological Diseases in the United States

Julia Fox, Elizabeth Mearns, Thomas Majda, Kate Rosettie, Nikki Win, Stacey Kowal

Neuroscience | Multiple Sclerosis

02:00 PM

Duration 1hr Denver, USA

The Safety Profile of Fenebrutinib in Patients With Multiple Sclerosis Is Consistent With Those In Previously Studied Autoimmune Indications

Jiwon Oh, Anastasiia Raievska, Malgorzata Sierzega, Joao Cerqueira, Claire S. Riley, Maresa Caunt, John N. Ratchford, Alexandra Goodyear, Konstantina Vanevski, Maria Pia Sormani, Gavin Giovanonni

Neuroscience | Multiple Sclerosis

Duration 60mins Denver, USA

Ocrelizumab in Patients With Early-Stage RRMS – Results From The Phase IIIb ENSEMBLE Trial and The Matched Real-World NTD MS Registry Cohort

HP Hartung, T Holmøy, J Wuerfel, Y Heer, S Braune, A Bergmann, M Zuercher, S. Guye, T Kuenzel, S Moore, T Vollmer, on behalf of the NTD study group

Neuroscience | Multiple Sclerosis

05:45 PM

Duration 1hr Denver, USA

A Two-Part, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Fenebrutinib (Part A) and the Effect of Fenebrutinib on the QT/QTc Interval in Healthy Participants (Part B)

Yan Xu, Denison Kuruvilla, John N Ratchford, Qi Qi, Lin Pan, Jiajie Yu

Neuroscience | Multiple Sclerosis

Duration 1hr Denver, USA

Burdens of Neuromyelitis Optica Spectrum Disorder: Real-World Perspectives From Caregivers

Anisha M. Patel, Ashley Martin, Kacper Perkowski, Kathryn Krupsky, Patrick Olsen, Shervin Gholizadeh, Jacinta Behne, Megan K. Behne, Kim Jackson-Matthews, Lisa McDaniel, Cori Woolf, Michael R. Yeaman

Neuroscience | Neuromyelitis Optica

Duration 60mins Denver, USA

LUMINESCE, a Phase 3 study of satralizumab▼ in generalized myasthenia gravis (gMG): Baseline Characteristics

Ali. A. Habib, Chongbo Zhao, Inmaculada Aban, Marcondes Cavalcante França Jr., Jorge Gustavo José, Gerd Meyer zu Hörste, Elżbieta Klimiec-Moskal, Michael T. Pulley, Darío Tavolini, Petranka Krumova, Siân Lennon-Chrimes, Jillian Smith, Ivana Vodopivec, Gian-Andrea Thanei, Gil I. Wolfe, Hiroyuki Murai

Neuroscience | Myasthenia gravis

Duration 60mins Denver, USA

Infection in NMOSD: Analyzing the patterns of infection in the SAkura studies, satralizumab▼ post-marketing data, and NMOSD US PharMetrics claims data

Benjamin M. Greenberg, Kazuo Fujihara, Brian Weinshenker, Francesco Patti, Ingo Kleiter, Jeffrey L. Bennett, Jacqueline Palace, Miriam Triyatni, Kathleen Blondeau, Alexander Burdeska, Innocent Ngwa, Gaëlle Klingelschmitt, Takashi Yamamura

Neuroscience | Neuromyelitis Optica

Duration 60mins Denver, USA

OCARINA I, Phase Ib Study: Dose Selection of Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis

SD Newsome, L Goldstick, B Townsend, D Zecevic, A Augustin, C Figueiredo, S Clinch, C Giacobino, O Bortolami, YA Shen, H Kletzl, R Bermel

Neuroscience | Multiple Sclerosis

Duration 60mins Denver, USA

Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With High-Activity, Early-Stage Relapsing-Remitting Multiple Sclerosis in the ENSEMBLE Study

HP Hartung, R Bermel, B Brochet, WM Carroll, MS Freedman, T Holmøy, R Karabudak, J Killestein, C Nos, F Patti, L Vanopdenbosch, T Kuenzel, K Kadner, I Kulyk, T Berger on behalf of the ENSEMBLE Investigators and Steering Committee

Neuroscience | Multiple Sclerosis

07:00 PM

Duration 12mins S31: Multiple Sclerosis: Therapeutics and Clinical Decision Making

Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis: Results of the Phase III OCARINA II Study

SD Newsome, E Krzystanek, K Selmaj, L Goldstick, C Figueiredo, B Townsend, C Wolf, D Zecevic, C Giacobino, O Bortolami, YA Shen, H Kletzl, S Clinch, D Centonze

Neuroscience | Multiple Sclerosis

07:12 PM

Duration 12mins S32: Autoimmune Neurology: NMOSD/MOGAD

Long-term efficacy of satralizumab▼ in patients with AQP4-IgG+ NMOSD: Updated analysis from the open-label SAkuraMoon study

Jacqueline Palace, Anthony Traboulsee, Albert Saiz, Jerome De Seze, Ingo Kleiter, Jeffrey L. Bennett, Daniela Stokmaier, Gaëlle Klingelschmitt, Audrey Yeo Te-ying, Ivana Vodopivec, Takashi Yamamura

Neuroscience | Neuromyelitis Optica

07:36 PM

Duration 12mins S31: Multiple Sclerosis: Therapeutics and Clinical Decision Making

Cerebrospinal Fluid and MRI Analyses of Fenebrutinib Treatment in Multiple Sclerosis Reveal Brain Penetration and Early Reduction of New Lesion Activity: Results From the Phase II FENopta Study

Amit Bar-Or, Michal Dufek, Hrvoje Budincevic, Jelena Drulovic, Mario Habek, Le H Hua, Martin S Weber, Piia Thomas, Julie Napieralski, David Clayton, Denison Kuruvilla, Qi Qi, Yan Xu, Alexandra Goodyear, Jiwon Oh

Neuroscience | Multiple Sclerosis

07:48 PM

Duration 12mins S31: Multiple Sclerosis: Therapeutics and Clinical Decision Making

10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-Term Efficacy and Safety Clinical Trial Data

SL Hauser, L Kappos, M Filippi, JS Wolinsky, MS Weber, JA Nicholas, C Chognot, HM Schneble, Q Wang, G Giovannoni, X Montalban

Neuroscience | Multiple Sclerosis

08:00 PM

Duration 12mins S30: Movement Disorders: Clinical Trials in Movement Disorders

Exploratory Analysis of PASADENA Open-label Extension Evaluating the Effect of Prasinezumab on the Progression of Motor Signs and Symptoms

Patrik Brundin

Neuroscience | Parkinson's Disease

10:30 PM

Duration 12mins S37: Emerging Therapies in Child Neurology

RAINBOWFISH: Primary efficacy and safety data in risdiplam▼-treated infants with presymptomatic spinal muscular atrophy (SMA)

L Servais, MA Farrar, RS Finkel, D Vlodavets, E Zanoteli, M Al-Muhaizea, APQC Araujo, L Nelson, B Jaber, K Gorni, H Kletzl, L Palfreeman, E Gaki, M Rabbia, D Summers, P Fontoura, E Bertini, on behalf of the RAINBOWFISH Study Group

Neuroscience | Spinal Muscular Atrophy

I am a healthcare professional

Notice

Cookies

External site

AAN 2024